Vertex Pharmaceuticals Stock Buy Hold or Sell Recommendation
| VRTX Stock | USD 480.35 1.30 0.27% |
Given the investment horizon of 90 days and your complete indifference towards market risk, our recommendation regarding Vertex Pharmaceuticals is 'Cautious Hold'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Vertex Pharmaceuticals given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Vertex Pharmaceuticals, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Vertex Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide. In addition, we conduct extensive research on individual companies such as Vertex and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Vertex Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
Vertex |
Execute Vertex Pharmaceuticals Buy or Sell Advice
The Vertex recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Vertex Pharmaceuticals. Macroaxis does not own or have any residual interests in Vertex Pharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Vertex Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Insignificant | Details | |
Volatility | Very steady | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Vertex Pharmaceuticals Trading Alerts and Improvement Suggestions
| The company reported the previous year's revenue of 11.02 B. Net Loss for the year was (535.6 M) with profit before overhead, payroll, taxes, and interest of 9.49 B. | |
| Vertex Pharmaceuticals currently holds about 9.77 B in cash with (492.6 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 38.06. | |
| Vertex Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Over 96.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from arstechnica.com: Claude 3.7 Sonnet debuts with extended thinking to tackle complex problems |
Vertex Pharmaceuticals Returns Distribution Density
The distribution of Vertex Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Vertex Pharmaceuticals' future price movements. The chart of the probability distribution of Vertex Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Vertex Pharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Vertex Pharmaceuticals returns is essential to provide solid investment advice for Vertex Pharmaceuticals.
| Mean Return | 0.08 | Value At Risk | -3.14 | Potential Upside | 2.57 | Standard Deviation | 2.17 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Vertex Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Vertex Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Vertex Pharmaceuticals, soars without any apparent reason? This usually happens because many institutional investors are aggressively trading Vertex Pharmaceuticals back and forth among themselves.
| Shares | Loomis, Sayles & Company Lp | 2024-12-31 | 3.8 M | Norges Bank | 2024-12-31 | 3.4 M | Amundi | 2024-12-31 | 3.3 M | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 3.2 M | Hhg Plc | 2024-12-31 | 2.8 M | Northern Trust Corp | 2024-12-31 | 2.7 M | Bank Of America Corp | 2024-12-31 | 2.4 M | Ubs Asset Mgmt Americas Inc | 2024-12-31 | 2.3 M | Massachusetts Financial Services Company | 2024-12-31 | 2.3 M | Capital World Investors | 2024-12-31 | 28.3 M | Vanguard Group Inc | 2024-12-31 | 23.3 M |
Vertex Pharmaceuticals Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 2.9B | 811.2M | 3.7B | (139.7M) | (5.8B) | (5.5B) | |
| Free Cash Flow | 3.0B | 2.4B | 3.9B | 3.3B | (790.3M) | (750.8M) | |
| Depreciation | 109.5M | 125.6M | 148.3M | 181.3M | 207.2M | 217.6M | |
| Capital Expenditures | 259.8M | 235M | 204.7M | 258.4M | 297.7M | 312.6M | |
| Net Income | 2.7B | 2.3B | 3.3B | 3.6B | (535.6M) | (508.8M) | |
| End Period Cash Flow | 6.0B | 6.8B | 10.5B | 10.4B | 4.6B | 4.8B | |
| Other Non Cash Items | (220.0M) | (5.8M) | 103.4M | (42.6M) | 900K | 855K | |
| Change To Inventory | (132.0M) | (92.8M) | (136.4M) | (322.9M) | (517.3M) | (491.4M) | |
| Dividends Paid | 20.8M | 10.0M | 264.9M | 102M | 117.3M | 123.2M | |
| Investments | 378.5M | (28.9M) | 227.3M | (2.1B) | (3.8B) | (3.6B) | |
| Change Receivables | (225.6M) | (223.4M) | (274.7M) | (358.6M) | (322.7M) | (306.6M) | |
| Net Borrowings | (35.0M) | (29.0M) | (24.4M) | (85.5M) | (77.0M) | (73.1M) | |
| Change To Netincome | 381.9M | 521.4M | 452.7M | 445.6M | 512.4M | 437.4M |
Vertex Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Vertex Pharmaceuticals or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Vertex Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Vertex stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.06 | |
β | Beta against Dow Jones | -0.09 | |
σ | Overall volatility | 2.21 | |
Ir | Information ratio | 0.03 |
Vertex Pharmaceuticals Volatility Alert
Vertex Pharmaceuticals currently demonstrates below-average downside deviation. It has Information Ratio of 0.03 and Jensen Alpha of 0.06. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Vertex Pharmaceuticals' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Vertex Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Vertex Pharmaceuticals Fundamentals Vs Peers
Comparing Vertex Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Vertex Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Vertex Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Vertex Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Vertex Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Vertex Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Vertex Pharmaceuticals to competition |
| Fundamentals | Vertex Pharmaceuticals | Peer Average |
| Return On Equity | -0.0315 | -0.31 |
| Return On Asset | 0.13 | -0.14 |
| Profit Margin | (0.05) % | (1.27) % |
| Operating Margin | 0.45 % | (5.51) % |
| Current Valuation | 119.32 B | 16.62 B |
| Shares Outstanding | 256.79 M | 571.82 M |
| Shares Owned By Insiders | 0.33 % | 10.09 % |
| Shares Owned By Institutions | 96.42 % | 39.21 % |
| Number Of Shares Shorted | 4.56 M | 4.71 M |
| Price To Earning | 24.57 X | 28.72 X |
| Price To Book | 7.54 X | 9.51 X |
| Price To Sales | 11.22 X | 11.42 X |
| Revenue | 11.02 B | 9.43 B |
| Gross Profit | 9.49 B | 27.38 B |
| EBITDA | 486.3 M | 3.9 B |
| Net Income | (535.6 M) | 570.98 M |
| Cash And Equivalents | 9.77 B | 2.7 B |
| Cash Per Share | 38.06 X | 5.01 X |
| Total Debt | 1.75 B | 5.32 B |
| Debt To Equity | 0.06 % | 48.70 % |
| Current Ratio | 4.70 X | 2.16 X |
| Book Value Per Share | 63.87 X | 1.93 K |
| Cash Flow From Operations | (492.6 M) | 971.22 M |
| Short Ratio | 2.92 X | 4.00 X |
| Earnings Per Share | (2.08) X | 3.12 X |
| Price To Earnings To Growth | 1.33 X | 4.89 X |
| Target Price | 497.91 | |
| Number Of Employees | 6.1 K | 18.84 K |
| Beta | 0.41 | -0.15 |
| Market Capitalization | 123.68 B | 19.03 B |
| Total Asset | 22.53 B | 29.47 B |
| Retained Earnings | 9.61 B | 9.33 B |
| Working Capital | 6.03 B | 1.48 B |
Note: Disposition of 2812 shares by Bozic Carmen of Vertex Pharmaceuticals at 420.58 subject to Rule 16b-3 [view details]
Vertex Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Vertex . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 22303.18 | |||
| Daily Balance Of Power | (0.13) | |||
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 481.12 | |||
| Day Typical Price | 480.86 | |||
| Price Action Indicator | (1.42) | |||
| Period Momentum Indicator | (1.30) | |||
| Relative Strength Index | 62.7 |
About Vertex Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Vertex Pharmaceuticals? Buying financial instruments such as Vertex Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Vertex Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run FinTech Thematic Idea Now
FinTech
High long term potential financial entities that are ranging from payment processing, investment management to commercial and investment banking. The FinTech theme has 69 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize FinTech Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Vertex Stock Analysis
When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.